# Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.

> **NCT03150329** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 52 (actual)

## Conditions studied

- Grade 3b Follicular Lymphoma
- Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL
- Recurrent Classic Hodgkin Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Follicular Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3a Follicular Lymphoma
- Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
- Recurrent Transformed Non-Hodgkin Lymphoma
- Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL
- Refractory Classic Hodgkin Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Follicular Lymphoma
- Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
- Refractory Transformed Non-Hodgkin Lymphoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Vorinostat

## Key facts

- **NCT ID:** NCT03150329
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-07-18
- **Primary completion:** 2023-06-23
- **Final completion:** 2026-07-01
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-09-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03150329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03150329, "Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03150329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*